SAP30L: A Potential Drug Target for Neurodegenerative Diseases

Target Name: SAP30L

NCBI ID: G79685

SAP30L

SAP30L: A Potential Drug Target for Neurodegenerative Diseases

SAP30L, or Sin3 corepressor complex subunit, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell proliferation and survival, and has been identified as a potential drug target in the field of neurodegenerative diseases.

SAP30L is a member of the SAP30 family of corepressor proteins, which are known for their ability to inhibit the activity of cell proliferation inhibitors, such as p21 and p53. This family of proteins is important for maintaining cell survival and has been implicated in a wide range of biological processes, including cell growth, apoptosis, and regeneration.

SAP30L is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is highly expressed in the brain, where it is found in the peri-synaptic zone, the site where neuron-to-neuron synapses Touch and meet. SAP30L is also expressed in the heart and kidneys, where it is involved in regulating the proliferation and survival of cardiac and renal cells.

SAP30L is a key regulator of cell proliferation and has been shown to play a role in a wide range of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It is thought to work by inhibiting the activity of p21, a protein that inhibits the activity of the tumor suppressor protein p53.

SAP30L is also involved in the regulation of cell apoptosis, which is the process by which cells die naturally. In neurodegenerative diseases, misregulated apoptosis can contribute to the progression of the disease. SAP30L has been shown to play a role in regulating apoptosis in the brain and has been implicated in the development of neurodegenerative diseases.

SAP30L is also involved in the regulation of cell migration, which is the movement of cells from the body's surface to sites of new growth and development. This is an important process for the development and maintenance of tissues and organs, and is implicated in a wide range of diseases, including cancer and neurodegenerative diseases.

SAP30L is a potential drug target because of its involvement in the regulation of cell proliferation and apoptosis. Drugs that target SAP30L have been shown to be effective in treating a wide range of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally , studies have shown that targeting SAP30L with small molecules has the potential to treat a wide range of other diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, SAP30L is a key regulator of cell proliferation and survival, and has been identified as a potential drug target in the field of neurodegenerative diseases. Further research is needed to understand the full role of SAP30L in these diseases and to develop effective treatments.

Protein Name: SAP30 Like

Functions: Functions as transcription repressor, probably via its interaction with histone deacetylase complexes (PubMed:16820529, PubMed:18070604). Involved in the functional recruitment of the class 1 Sin3-histone deacetylase complex (HDAC) to the nucleolus (PubMed:16820529). Binds DNA, apparently without sequence-specificity, and bends bound double-stranded DNA (PubMed:19015240). Binds phosphoinositol phosphates (phosphoinositol 3-phosphate, phosphoinositol 4-phosphate and phosphoinositol 5-phosphate) via the same basic sequence motif that mediates DNA binding and nuclear import (PubMed:19015240, PubMed:26609676)

The "SAP30L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SAP30L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets